Genzyme Corporation
Genzyme Provides Outlook for Long-Term Growth at its Analyst Day Meeting
Published in Blood Weekly, May 21st, 2009
Genzyme Corp. (NASDAQ: GENZ) today outlined its plans for continued sustainable growth across each of its businesses, provided updates on anticipated near-term regulatory milestones, and shared new clinical data at its Analyst Day Meeting. Genzyme’s growth is being driven by increasing sales of existing products, the launch of new treatments, and continued operating leverage from the company’s global infrastructure.
The company reaffirmed its goal of $7 billion in annual revenue by 2011 and more than 20 percent growth in compound non-GAAP earnings per diluted share (EPS) through 2011. In response to investor feedback, Genzyme is simplifying its presentation of non-GAAP...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
Source: Blood Weekly (2009-05-21)
More Articles from Blood Weekly
- American Society of Nephrology
Simultaneous transplant gives best results in diabetics with kidney disease - Canadian Medical Association Journal
Drugs to combat anemia in cancer patients increase risk of death - Scripps Research Institute
Scripps Research scientists determine workings of potentially useful virus - World Journal of Gastroenterology
A new light on the mechanisms of early stage liver reperfusion injury - Antifungals
Reports on antifungals findings from University of Sao Paulo provide new insights - Biomedical Companies
Response Biomedical Announces Proposed Unit Offering - More from this issue of Blood Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
